Scholar Rock Holding Corporation (SRRK)

US — Healthcare Sector
Peers: TCRR  RVMD  BDTX  BCEL  PASG  GLUE  DSGN  HOWL  IKNA  STOK  IDYA  ANAB  MGTX  KROS  FIXX  RNA  IGMS  CERE  CGEM  MLYS  RLAY  PLRX  ARVN 

Automate Your Wheel Strategy on SRRK

With Tiblio's Option Bot, you can configure your own wheel strategy including SRRK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SRRK
  • Rev/Share 0.0
  • Book/Share 2.7927
  • PB 10.6849
  • Debt/Equity 0.2022
  • CurrentRatio 10.253
  • ROIC -0.7195

 

  • MktCap 2833176704.0
  • FreeCF/Share -2.0582
  • PFCF -12.3083
  • PE -12.6333
  • Debt/Assets 0.1549
  • DivYield 0
  • ROE -1.1822

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Reiterated SRRK H.C. Wainwright -- Buy $30 $35 Oct. 7, 2024

News

Scholar Rock Holding Corporation (SRRK) Q1 2025 Earnings Call Transcript
SRRK
Published: May 14, 2025 by: Seeking Alpha
Sentiment: Neutral

Scholar Rock Holding Corporation (NASDAQ:SRRK ) Q1 2025 Earnings Conference Call May 14, 2025 8:15 AM ET Company Participants Rushmie Nofsinger - VP, Corporate Affairs and IR David Hallal - CEO Akshay Vaishnaw - President of R&D Keith Woods - COO Vikas Sinha - CFO Conference Call Participants Allison Bratzel - Piper Sandler Michael Yee - Jefferies Tessa Romero - JPMorgan David Nierengarten - Wedbush Gary Nachman - Raymond James Kripa Devarakonda - Truist Marc Frahm - TD Cowen Andres Maldonado - H.C. Wainwright Dennis Kennedy - LifeSci Capital Operator Ladies and gentlemen, thank you for standing by.

Read More
image for news Scholar Rock Holding Corporation (SRRK) Q1 2025 Earnings Call Transcript
Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025
SRRK
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that management will host a conference call to discuss its first quarter 2025 financial results and provide a business update on Wednesday, May 14, 2025, at 8:15am ET. To access the live conference call, participants may register here. The live audio web.

Read More
image for news Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025
Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth
SRRK
Published: April 28, 2025 by: Business Wire
Sentiment: Neutral

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, announced today that David Hallal has been appointed Chief Executive Officer succeeding Jay Backstrom, M.D. David Hallal has served as Chairman of the Board at Scholar Rock since 2017 and just prior to that spent more than a decade as CEO, COO, and CCO of Alexion buildi.

Read More
image for news Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth
Scholar Rock Holding Corporation (SRRK) Q4 2024 Earnings Call Transcript
SRRK
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral

Scholar Rock Holding Corporation. (NASDAQ:SRRK ) Q4 2024 Earnings Conference Call February 27, 2025 8:15 AM ET Company Participants Jay Backstrom - President & CEO Ted Myles - COO & CFO Tracey Sacco - Chief Commercial Officer Conference Call Participants Allison Bratzel - Piper Sandler Michael Yee - Jefferies Tessa Romero - JPMorgan Gary Nachman - Raymond James Operator Good morning and welcome to Scholar Rock's Fourth Quarter Financial Results and Business Update Call.

Read More
image for news Scholar Rock Holding Corporation (SRRK) Q4 2024 Earnings Call Transcript

About Scholar Rock Holding Corporation (SRRK)

  • IPO Date 2018-05-25
  • Website https://scholarrock.com
  • Industry Biotechnology
  • CEO Mr. David L. Hallal
  • Employees 128

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.